Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis

Casaretto, L.; Sousa, Patricia; Mari, Jair J.

doi:10.1590/s0100-879x2006000400002

Cited by 32 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A high incidence of GC is observed in individuals between 40 and 60 years of age (1). Each year, ~900,000 new cases of GC are diagnosed, while ~700,000 patients succumb to GC globally (2), with half of these mortalities occurring in Asia.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of MYC binding protein promotes invasion and migration in gastric cancer

et al. 2018

View full text Add to dashboard Cite

Abstract. Gastric cancer (GC) is the second leading cause of cancer-associated mortality worldwide. Although the mortality rate of patients with GC has improved, it remains a significant health issue. The MYC proto-oncogene protein serves key roles in cellular proliferation, differentiation, transformation and apoptosis. Previous studies have identified the abnormal expression of MYC-binding protein (MYCBP) during tumorigenesis in multiple types of cancer. Furthermore, evidence demonstrates that the abnormal expression of MYCBP contributes to the invasion and migration of human cancer types, including colon cancer and glioma; however, its influence on GC remains unclear. In the present study, the expression of MYCBP in GC cells and tissues was analyzed by reverse transcription-quantitative polymerase chain reaction. Additionally, GC cell lines were transfected with small interfering RNAs against MYCBP or lymphoid enhancer-binding factor 1 (LEF-1) and assessed by in vitro transwell migration and invasion assays. The results indicated that the expression of MYCBP in GC cells and tissues was markedly increased compared with a normal gastric epithelial cell line and adjacent normal gastric mucosal tissues, respectively. Furthermore, MYCBP downregulation notably inhibited the metastatic capacity of GC cells, and LEF-1 knockdown was found to downregulate the expression of MYCBP. On the basis of the findings of the present study, MYCBP may be a direct target of the β-catenin/LEF-1 pathway via binding LEF-1, and could potentially be used as a biomarker for the diagnosis and prognosis of GC.

show abstract

Section: Introductionmentioning

confidence: 99%

Overexpression of MYC binding protein promotes invasion and migration in gastric cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…According to results of randomized studies and meta-analyses, in metastatic gastric cancer cases, chemotherapy is more effective than supportive treatment with regard to both quality of life and survival. 5,6 5-Flourouracil and platins are most frequently used drugs. Then, it was demonstrated that addition of taxane groups chemoteurpatic drugs to these (docetaxel or paclitaxel) may improve treatment outcomes.…”

Section: Introductionmentioning

confidence: 99%

Reduced Doses of Docetaxel and Cisplatinum Plus 5 Fluorouracil Combination Chemotherapy in Metastatic Esophagogastric Adenocarcinoma: The Impact on Outcomes

Eren¹

2017

UHOD

View full text Add to dashboard Cite

Docetaxel-cisplatin-5-fluorourasil (DCF) protocol is one of the standard regimen at present however it is difficult to administer owing to high toxicity rates. The aim of study was to modify the dose of DCF regimen in order to render it more tolerable and to evaluate the efficacy and tolerability of modified DCF (mDCF) protocol. 267 patients followed in Ankara Numune Hospital were included in the study.All patients were administered mDCF regimen as metastatic first line treatment. Doses in mDCF arm was as follows: docetaxel 60 mg/ m 2 1. day, cisplatin 60 mg/m 2 1. day and 5-fluorouracil 600 mg/m 2 /day (1-5 days) every three weeks In the study, files of overall 267 patients who did not previously receive treatment were evaluated retrospectively. Median number of cycles in all patients was 6 (range 2-10). Median age of patients was 55 (range 22-76). Median follow up period was 9 months. Complete response 5 (1.9%) patients, partial response 74 (27.7%) patients and stable disease 95 (35.6%) patient. Median PFS was 6.0 (95%CI, 5.3-6.6) months, and median OS 10.0 (95% CI, 8.8-11.1) months. Parameters effect in univariate analysis were submitted to multivariate analysis results were CEA, grade, ECOG effective on OS. Grade 3-4 neutropenia was found 28.1%, anemia 11.6%, thrombocytopenia 4.1% and Febrile neutropenia 4.9%. Although mDCF regimen seems to be as effective as original DCF regimen, grade 3-4 toxicity rates were found to be lower. mDCF may be preferred as a tolerable and effective regimen in ECOG 0-2 metastatic gastric cancers. (1-5 günler) üç hastada bir olarak verildi. Çalışmada daha önce tedavi almamış 267 hastanın dosyaları retrospektif olarak incelendi.Hastaların aldığı median kür sayısı 6 (2-10), median yaş 55 (22-76) idi. Median takip süresi 9 ay idi. Tam yanıt 5 (1.9%) hastada, parsiyel yanıt 74 (%27.7) hastada, stabil hastalık 95 (%35.6) hastada tespit edildi. Median PFS 6.0 (%95 CI, 5.3-6.6) ay, median OS 10.0 (%95 CI, 8.8-11.1) ay olarak bulundu. Multivariate analizde OS üzerine etki eden faktörler CEA düzeyi, tümör greydi ve ECOG skoruydu.Grade 3-4 nötropeni %28.1, anemi %11.6, trombositopeni %4.1 olarak bulundu. Febril nötropeni oranı %4.9 idi. mDCF rejimi orijinal DCF rejimi kadar etkilidir, grade 3-4 toksisite oranları daha düşüktür. mDCF, ECOG 0-2 metastatik mide kanserinde etkili ve daha tolerabl bir rejim olarak tercih edilebilir.

show abstract

“…To prolong the survival of these patients, it is important to continue effective chemotherapy for as long as possible. Casaretto et al [1] reported that chemotherapy increased the 1-year survival rate, provided a longer symptom-free period and improved the quality of life (QOL) of patients. Recently, S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS) trial identified the S-1 plus cisplatin regimen, which comprises S-1 at a dose of 40 -60 mg/m 2 , in a 5-week cycle (3 weeks on and 2 weeks off), and cisplatin at a dose of 60 mg/m 2 cisplatin on day 8, as a standard first-line treatment for unresectable gastric cancer in Japan [2].…”

Section: Introductionmentioning

confidence: 99%

Effect of Fucoidan Dietary Supplement on the Chemotherapy Treatment of Patients with Unresectable Advanced Gastric Cancer

Ikeguchi¹,

Saito²,

Miki³

et al. 2015

JCT

View full text Add to dashboard Cite

In Japan, S-1 plus cisplatin has become a standard regimen for the treatment of unresectable advanced gastric cancer; however, many patients are unable to continue effective chemotherapy because of the regimen's severe side effects. Thus, control of drug toxicity is key to prolonging patient survival. Fucoidan is a major sulfated polysaccharide found in brown seaweeds and has a wide range of biological activities. In the present study, we analyzed the effect of fucoidan on suppressing the toxicity of chemotherapy drugs. Twenty-four patients with unresectable advanced gastric cancer underwent treatment with S-1 plus cisplatin and were randomly allocated into a fucoidan treatment group (n = 12) or a control group without fucoidan treatment (n = 12). The study results demonstrated that fucoidan controlled the occurrence of fatigue during chemotherapy and patients could continue chemotherapy for longer time periods by maintaining the patients' favorable nourishment status. As a result, the survival of patients with fucoidan treatment was longer than that of patients without fucoidan. Thus, fucoidan should be included as a key food supplement for patients with gastrointestinal carcinomas who are suffering from the adverse side effects of chemotherapy.

show abstract

Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis

Cited by 32 publications

References 15 publications

Overexpression of MYC binding protein promotes invasion and migration in gastric cancer

Overexpression of MYC binding protein promotes invasion and migration in gastric cancer

Reduced Doses of Docetaxel and Cisplatinum Plus 5 Fluorouracil Combination Chemotherapy in Metastatic Esophagogastric Adenocarcinoma: The Impact on Outcomes

Effect of Fucoidan Dietary Supplement on the Chemotherapy Treatment of Patients with Unresectable Advanced Gastric Cancer

Contact Info

Product

Resources

About